The European Union’s drug regulator said Wednesday that it found a “possible link” between the AstraZeneca coronavirus vaccine and a rare blood clotting disorder, but recommended that vaccinations continue in adults, saying the benefits of the shot still outweigh risks.
The European Medicines Agency (EMA) described the clots as “very rare” side effects. It said most of the cases reported have occurred in women under 60 within two weeks of vaccination — but based on the currently available evidence, it was not able to identify specific risk factors.
But, it placed no new age restrictions on using the vaccine in people 18 and over, as some countries have done.
Crystal Goomansingh explains the findings.
For more info, please go to https://globalnews.ca/news/7742716/astrazeneca-ema-vaccine-blood-clots-investigation/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews
The European Medicines Agency (EMA) described the clots as “very rare” side effects. It said most of the cases reported have occurred in women under 60 within two weeks of vaccination — but based on the currently available evidence, it was not able to identify specific risk factors.
But, it placed no new age restrictions on using the vaccine in people 18 and over, as some countries have done.
Crystal Goomansingh explains the findings.
For more info, please go to https://globalnews.ca/news/7742716/astrazeneca-ema-vaccine-blood-clots-investigation/
Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc
Like Global News on Facebook HERE: http://bit.ly/255GMJQ
Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt
Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB
#GlobalNews
- Category
- U.S. & Canada
- Tags
- Europe, European Medicines Agency, EMA
Sign in or sign up to post comments.
Be the first to comment